Myositis — Polymyositis and Dermatomyositis

Mechanistic groupings

• Primary autoimmune (idiopathic): The largest group — loss of tolerance to muscle antigens in a genetically susceptible host, producing the CD8+/HLA-I cytotoxic pattern of PM and the complement-mediated microangiopathy of DM. Captured by the ACR/EULAR 2017 classification criteria for idiopathic inflammatory myopathies, which weight age of onset, weakness pattern, rash, CK, and biopsy.
• Paraneoplastic (cancer-associated myositis): Tumor antigens cross-reactive with regenerating muscle drive autoimmunity; adenocarcinomas (breast, ovarian, lung, gastric, colorectal, nasopharyngeal in Asian populations) predominate. Anti-TIF1-γ and anti-NXP2 antibodies mark the highest-risk phenotype in adults.
• Drug/toxin-triggered: Statins can precipitate anti-HMGCR immune-mediated necrotizing myopathy, which persists after drug withdrawal — distinct from self-limited statin myalgia. Immune checkpoint inhibitors (anti–PD-1/CTLA-4) cause an immune-related myositis that may overlap with myocarditis and myasthenia.
• Infection-associated: Picornaviruses (coxsackie), influenza, HIV, and HTLV-1 are proposed molecular-mimicry triggers; HIV and HTLV-1 myositis are clinically indistinguishable from PM.
• Overlap connective tissue disease: Myositis as a component of SLE, systemic sclerosis, Sjögren, or MCTD (anti-U1-RNP, anti-PM/Scl).

Non-modifiable risk factors

• Age: Bimodal — juvenile DM in childhood, adult peak in middle age; malignancy risk rises sharply with older age at DM onset.
• Sex: Female predominance (roughly 2:1).
• Genetics: HLA-DRB1*03:01 and the 8.1 ancestral haplotype (HLA-B8/DR3), particularly for anti-Jo-1 disease; family history of autoimmunity.

Modifiable / exposure-related

• Ultraviolet light: Correlates with DM (and anti-Mi-2) prevalence at lower latitudes and provokes cutaneous flares — photoprotection is standard advice.
• Smoking: Enriched among anti-synthetase/anti-Jo-1 patients carrying HLA-DRB1*03:01.
• Drug exposure: Statins and checkpoint inhibitors, as above; discontinuation is the first therapeutic lever.
• Cancer screening status: Not a cause but a modifiable stem detail — the USPSTF age- and sex-appropriate screening battery should be current in every newly diagnosed adult with DM.

• CD8+ T-cell mediated cytotoxicity: In polymyositis, autoreactive CD8+ T lymphocytes directly attack muscle fibers expressing HLA-I antigens, leading to fiber necrosis and inflammation. This is the hallmark pathophysiologic mechanism—muscle inflammation is primarily cytotoxic T-cell driven rather than antibody-driven.

• Antibody-mediated complement activation: In dermatomyositis, the primary mechanism differs: immune complexes activate complement (C5b-9) in the perifascicular regions and at the dermal-epidermal junction, causing microinfarction of muscle fibers and characteristic skin pathology. This explains why DM affects perifascicular muscle regions preferentially.

• Myositis-specific autoantibodies (MSAs): Patients develop pathogenic antibodies against muscle-associated antigens including anti-Jo-1 (histidyl-tRNA synthetase), anti-Mi-2, anti-SRP (signal recognition particle), and others. These antibodies correlate with disease phenotype and prognosis, and anti-Jo-1 is associated with the "antisynthetase syndrome" (myositis + arthritis + Raynaud's + interstitial lung disease + mechanic's hands).

• Genetic predisposition and environmental triggers: Strong association with HLA-DRB1 and HLA-DQA1 alleles; viral infections (particularly picornaviruses), UV exposure, and medications (statins, immunotherapy) proposed as triggers that break tolerance in genetically susceptible individuals.

• Inflammatory cascade amplification: Activated T cells and macrophages produce IL-1, IL-6, and TNF-α, perpetuating muscle inflammation, endothelial injury, and capillary dropout that leads to muscle ischemia and necrosis.

• Proximal muscle weakness: Insidious onset of symmetric proximal weakness affecting hip, shoulder, and thigh muscles—patients report difficulty climbing stairs, rising from chairs, or combing hair. Weakness typically develops over weeks to months and may be accompanied by muscle pain or tenderness (myalgia), though pain is variable.

• Pathognomonic dermatologic manifestations of dermatomyositis:
• Heliotrope rash: Violaceous (purple) erythema of upper eyelids with periorbital edema—one of the most classic exam findings
• Gottron papules: Scaly, erythematous papules overlying dorsal interphalangeal and metacarpophalangeal joints (similar to lupus but more raised/scaly)
• Shawl sign: V-shaped erythema over anterior chest and shoulders
• Mechanic's hands: Hyperkeratosis, fissuring, and scaling of lateral fingers and palms (associated with anti-Jo-1 antibodies and antisynthetase syndrome)

• Systemic and pulmonary manifestations: Interstitial lung disease (ILD) occurs in 5-15% of PM and 10-15% of DM, presenting as dyspnea and restrictive pattern on PFTs; dysphagia from pharyngeal muscle involvement (aspiration risk); low-grade fever; arthralgias/arthritis; Raynaud's phenomenon in subset with antisynthetase antibodies.

• Important clinical pearls: Distal muscle weakness is atypical and should prompt consideration of inclusion body myositis (IBM) instead. Polymyositis without skin involvement requires exclusion of other myopathies (muscular dystrophies, toxic myopathies). Juvenile dermatomyositis often presents more acutely with severe inflammation and lipodystrophy but has better prognosis than adult-onset.

• Clinical presentation plus supportive investigations: Diagnosis requires proximal muscle weakness and at least 2-3 of: (1) elevated creatine kinase (CK, often markedly elevated 5-50× upper limit of normal), (2) myopathic electromyography (EMG) pattern with short-duration, low-amplitude, polyphasic motor action potentials and early recruitment, (3) characteristic muscle biopsy findings, (4) typical skin rash (for DM).

• Myositis-specific autoantibodies and myositis-associated antibodies: Anti-Jo-1, anti-Mi-2, anti-SRP, anti-HMGCR, and others are highly specific and present in ~50-60% of PM/DM cases; their absence does not exclude diagnosis. Anti-Mi-2 associated with better prognosis; anti-SRP and anti-HMGCR associated with severe disease; anti-Jo-1 defines antisynthetase syndrome. Antinuclear antibody (ANA) positive in ~50-70% of cases.

• Muscle biopsy (gold standard): Shows endomysial inflammation with CD8+ T-cell infiltration in PM (invading non-necrotic fibers), perifascicular atrophy and complement deposition at microvasculature in DM, and fiber necrosis with regenerating fibers. MRI of affected muscles can aid biopsy site selection and has become increasingly used as an alternative screening modality.

• Important diagnostic considerations: CK >1000 IU/L and myopathic EMG pattern help distinguish myositis from polymyalgia rheumatica (which has normal CK and normal EMG). Screen all adult DM patients for malignancy (breast, lung, ovarian, gastric) with age-appropriate cancer screening; risk highest in first 1-2 years after DM diagnosis. Inclusion body myositis presents with distal weakness and has characteristic "rimmed vacuoles" on biopsy—clinically distinct entity despite myositis name.

• First-line: Corticosteroids: High-dose prednisone (0.5-1 mg/kg/day, typically 40-60 mg daily) or equivalent is standard initial therapy; taper slowly over months guided by clinical improvement and CK normalization. Response usually evident within 4-12 weeks. Steroid-sparing agents introduced early to minimize long-term corticosteroid toxicity.

• Steroid-sparing immunosuppressive agents: Methotrexate (15-25 mg weekly) or azathioprine (1-3 mg/kg/day) added as adjunctive therapy in most patients; allow dose reduction of corticosteroids. IV immunoglobulin (IVIG, 2 g/kg monthly) particularly useful for refractory disease, dermatomyositis (especially with severe cutaneous involvement), and statin-induced myositis. Mycophenolate mofetil increasingly used due to good efficacy and tolerability.

• Adjunctive and refractory disease management: Hydroxychloroquine (200-400 mg daily) helps cutaneous manifestations of dermatomyositis. TNF-α inhibitors (etanercept, infliximab) and newer agents (rituximab for anti-Jo-1+ disease, abatacept) reserved for refractory cases. Patients with ILD may benefit from aggressive immunosuppression with cyclophosphamide in severe cases.

• Special populations and situations: Juvenile DM often has more aggressive early course but better long-term prognosis—requires careful monitoring for calcinosis as complication. Statin-induced myositis may improve with statin discontinuation ± IVIG; anti-HMGCR antibodies predict more severe, refractory disease. ILD requires concurrent pulmonologist input; mycophenolate preferred over methotrexate when significant ILD present. Aspiration precautions and swallow evaluation critical when pharyngeal involvement present.

• The buzzword triad: Heliotrope rash + Gottron papules + symmetric proximal weakness = dermatomyositis, full stop. Shawl sign, V-sign, and mechanic's hands are the supporting cast; mechanic's hands should immediately redirect you to anti-Jo-1 and the antisynthetase syndrome.
• Single best next step in a weak patient: Serum CK. It is cheap, markedly elevated in active PM/DM, and immediately separates inflammatory myopathy from polymyalgia rheumatica, in which CK is normal and the complaint is stiffness/pain rather than true weakness.
• The one association examiners test: Adult dermatomyositis and occult malignancy, greatest in the first years after diagnosis. The expected answer is completing USPSTF age- and sex-appropriate screening plus directed evaluation (chest/abdomen/pelvis imaging, and in women, pelvic imaging); anti-TIF1-γ or anti-NXP2 positivity raises that suspicion further.
• Anti-Jo-1 means look at the lungs: Order PFTs and high-resolution CT — interstitial lung disease, not muscle weakness, drives mortality in antisynthetase syndrome, and the ACR's guidance on ILD in systemic autoimmune rheumatic disease supports screening symptomatic and high-risk patients.
• Anti-MDA5 amyopathic DM: Skin ulcers and palmar papules with little or no weakness and a near-normal CK, but rapidly progressive ILD. Do not be reassured by a normal CK.

Distractors to avoid

• Inclusion body myositis: Older man, distal and asymmetric weakness (finger flexors, quadriceps), only mildly elevated CK, rimmed vacuoles on biopsy, and — the key discriminator — no response to steroids.
• Steroid myopathy: Worsening weakness on prednisone with a normal or falling CK is drug toxicity, not a flare; the wrong answer is escalating the steroid dose.
• Statin myopathy: If weakness and CK persist or worsen after stopping the statin, test for anti-HMGCR necrotizing myopathy rather than declaring drug intolerance.
• Biopsy technique: Sample the contralateral muscle to the one studied by EMG — needle trauma creates inflammatory artifact.